News Vertex licenses back CRISPR compounds from German Merck US pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Germany’s Merck KGaA.
Partner Content Partner Content Dr. Dana Carroll to deliver keynote on challenges in Program... 2nd Genome Editing & Engineering Conference is back!
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
